Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: A dose-response study

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 841-847

  Whale, Christopher I ^a,b   Sovani, Milind P ^b   Mortimer, Kevin J ^b   Harrison, Timothy W ^b   Tattersfield, Anne E ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

2 agonists; COPD; Formoterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART RATE; HUMAN; MAINTENANCE THERAPY; MALE; OXYGEN SATURATION; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TREMOR; WALKING;

ADMINISTRATION, INHALATION; AGED; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 43549104866     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03081.x     Document Type: Article

References (28)

1. Dahl R, Greenhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164: 778 84.
2. D'Urzo AD, Cristina De Salvo M, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001 119: 1347 56.
3. National Institute of Clinical Excellence. Chronic Obstructive Pulmonary Disease. Management of Chronic Obstructive Pulmonary Disease in adults in primary and secondary care. Clinical Guideline 12. 2004. Available at http://www.nice.org.uk/CG012NICEguidelines (last accessed: January 2007).
4. Aalbers R, Ayers J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: a randomised, controlled, 3-month trial. Eur Respir J 2002 9: 178 85.
5. Cazzola M, Grella E, Matera MG, Mazzarella G, Marsico SA. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. Pulm Pharmacol Ther 2002 15: 97 102.
6. Cazzola M, Centanni S, Regorda C, di Marco F, di Perna F, Carlucci P, Boveri B, Santus P. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther 2001 14: 41 5.
7. Tattersfield AE, Lofdahl C-G, Postma DS, Eivindson A, Schreurs AGM, Rasidakis A, Ekstrom T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001 357: 257 61.
8. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, Bengtsson T, Rabe KF. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005 99: 1511 20.
9. Schmekel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax 1991 46: 225 8.
10. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002 166: 111 7.
11. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, Wise RA. Six-minute walk distance in chronic obstructive pulmonary disease. Reproducibility and effect of walking course layout and length. Am J Crit Care Med 2003 167: 1522 7.
12. 1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987 42: 487 90.
13. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994 49: 771 4.
14. Cazzola M, Matera M, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995 89: 357 62.
15. Boyd G, Morice AH, Poundsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease. Eur Respir J 1997 10: 815 21.
16. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000 55: 650 6.
17. Bremner P, Woodman K, Burgess C, Crane J, Purdie G, Pearce N, Beasley R. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993 6: 204 10.
18. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000 56: 363 70.
19. Totterman K, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998 12: 573 9.
20. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998 54: 141 7.
21. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999 160: 244 9.
22. Maesen FPV, Costongs R, Smeets JJ, Brombacher PJ, Zweers PGMA. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991 99: 1367 73.
23. Malolepszy J, Boszormenyi Nagy G, Selroos O, Larsson P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 2001 18: 928 34.
24. Harvey JE, Baldwin CJ, Wood PJ, Alberti KGMM, Tattersfield AE. Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. Clin Sci 1981 60: 579 85.
25. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989 140: 586 92.
26. 2-agonists in asthma. N Engl J Med 1992 327: 1204 8.
27. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxaemia. Chest 1998 114: 411 5.
28. Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988 138: 850 5.